However, concomitant treatment with the CCR4 antagonist SP50 [20,21] significantly reduced fungal burden and conferred full protection against infection (Figure 1), thus confirming the vaccine adjuvant properties of CCR4 antagonists. The gene discussed is CCR4; the disease is infection.